By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Northwest Biotherapeutics, Inc. 

21720 23rd Drive SE
Suite 100
Bothell  Washington  98021  U.S.A.
Phone: 425-608-3000-or-877-606-9246-Toll-Free Fax: 425-608-3026


SEARCH JOBS

Northwest Biotherapeutics, Inc is a clinical stage biotechnology company focused on the development of personalized cancer vaccines designed to treat a broad range of solid tumor cancers.

YEAR FOUNDED:

March 18, 1996

LEADERSHIP:

Founder: Alton Boynton

CEO: Hua Bai

CEO: Linda Powers

CTO: Marnix Bosch

CSO (Scientific): Alton Boynton

CLINICAL TRIAL:

Please click here for clinical trial information.

PRODUCTS:

All Products

FOLLOW NORTHWEST BIOTHERAPEUTICS:





Key Statistics


Email:
Ownership: Public

Web Site: NW Bio
Employees:
Symbol: NWBO
 



Industry
Services


Collaborations

Cytogen Corporation  Development of ex vivo prostate cancer immunotherapy





Company News
NW Bio (NWBO) Has Closed On Its Registered Direct Offering Of $7.5 Million With Institutional Investors 3/23/2017 11:58:06 AM
NW Bio (NWBO) Announces Registered Direct Offering Of $7.5 Million 3/17/2017 9:14:41 AM
NW Bio (NWBO) Announces Registered Direct Offering Of $7.5 Million 3/17/2017 8:52:19 AM
NW Bio (NWBO) Reaches Agreement With Convertible Note Holders 3/10/2017 6:43:19 AM
FDA Lifts Clinical Hold on NW Bio (NWBO)'s Phase III Cancer Vaccine Trial 2/6/2017 8:22:45 AM
NW Bio (NWBO) Announces A Registered Direct Offering Of $10.0 Million With Institutional Investors 12/20/2016 11:42:30 AM
NW Bio (NWBO) Announces Initiation Of Trading On The OTCQB Marketplace Starting On Monday Morning, December 19, 2016 12/19/2016 11:51:35 AM
NW Bio (NWBO) Provides Update About Phase 3 Trial Of DCVax-L For Newly Diagnosed Glioblastoma Multiforme Brain Cancer 12/8/2016 11:37:51 AM
NW Bio (NWBO) Announces Decision To Voluntarily Withdraw From Nasdaq Listing And Begin Trading On OTC Market 12/8/2016 8:14:13 AM
NW Bio (NWBO) Announces Phase II Clinical Trial Program Combining DCVax-L And Pembrolizumab (Keytruda) For Colorectal Cancer 11/17/2016 8:16:28 AM
12345678910...
//-->